The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Medrek, Catharina ^a   Pontén, Fredrik ^b   Jirström, Karin ^a   Leandersson, Karin ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

CD163; CD68; Tumor associated macrophages; Tumor stroma

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CELL INFILTRATION; CELLULAR DISTRIBUTION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STROMA; SWEDEN; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR STROMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BREAST NEOPLASMS; FEMALE; HUMANS; MACROPHAGES; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84864828790     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-306     Document Type: Article

References (31)

1. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1):71-78. 10.1038/nrc1256, 14708027.
2. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006, 42(6):717-727. 10.1016/j.ejca.2006.01.003, 16520032.
3. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1):23-35. 10.1038/nri978, 12511873.
4. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000, 67(1):97-103.
5. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 2004, 122(5):794-801. 10.1309/QHD6YFN81KQXUUH6, 15491976.
6. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 2005, 29(5):617-624. 10.1097/01.pas.0000157940.80538.ec, 15832085.
7. Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA, Tak PP, Baeten DL. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 2012, 375(1-2):196-206.
8. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196(3):254-265. 10.1002/path.1027, 11857487.
9. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56(20):4625-4629.
10. Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 1997, 50(8):669-673. 10.1136/jcp.50.8.669, 500114, 9301551.
11. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150. 10.1200/JCO.2005.05.2308, 16682732.
12. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993, 81(6):1607-1613.
13. Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009, 27(20):3330-3337. 10.1200/JCO.2008.19.9919, 19528371.
14. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007, 5:62. 10.1186/1479-5876-5-62, 2212626, 18047662.
15. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011, 121(2):784-799. 10.1172/JCI43757, 3026724, 21266779.
16. Svensson KJ, Christianson HC, Kucharzewska P, Fagerstrom V, Lundstedt L, Borgquist S, Jirstrom K, Belting M. Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol 2011, 39(6):1421-1428.
17. Gronberg M, Fjallskog ML, Jirstrom K, Janson ET. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. ActaOncol 2012, 51(3):386-393.
18. Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer 2010, 10:639. 10.1186/1471-2407-10-639, 2999619, 21092276.
19. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7(1-2):4-13. 2705275, 19574486.
20. Jirstrom K, Ryden L, Anagnostaki L, Nordenskjold B, Stal O, Thorstenson S, Chebil G, Jonsson PE, Ferno M, Landberg G. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005, 58(11):1135-1142. 10.1136/jcp.2005.027185, 1770762, 16254100.
21. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24(29):4660-4671. 10.1038/sj.onc.1208561, 15897907.
22. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5(6):607-616. 10.1016/j.ccr.2004.05.015, 15193263.
23. Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R. NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res 2005, 33(Database issue):D562-D566. 539976, 15608262.
24. Maniecki MB, Moller HJ, Moestrup SK, Moller BK. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 2006, 211(6-8):407-417.
25. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11(10):889-896. 10.1038/ni.1937, 20856220.
26. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G, Inoue M. orrelation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 2004, 24(5C):3335-3342.
27. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 2003, 23(6D):5015-5022.
28. Steele RJ, Eremin O, Brown M, Hawkins RA. Oestrogen receptor concentration and macrophage infiltration in human breast cancer. Eur J Surg Oncol 1986, 12(3):273-276.
29. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 2011, 128(3):703-711. 10.1007/s10549-010-1154-y, 20842526.
30. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol 2012, 38(4):307-313. 10.1016/j.ejso.2012.01.002, 22264965.
31. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8(8):618-631. 10.1038/nrc2444, 18633355.